Credit Suisse Ag Alnylam Pharmaceuticals, Inc. Put Options Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2021 Nov 12, 2021	SELL	$169.75 - $207.73 $611,100 - $747,828	-3,600 Reduced 12.63%	24,900 $4.7 Million
Q2 2021 Aug 16, 2021	SELL	$128.63 - $176.89 $5.93 Million - $8.15 Million	-46,100 Reduced 61.8%	28,500 $4.83 Million
Q1 2021 May 14, 2021	SELL	$126.83 - $175.69 $5.53 Million - $7.66 Million	-43,600 Reduced 36.89%	74,600 $10.5 Million
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $14.1 Million - $16.9 Million	114,900 Added 3481.82%	118,200 $15.4 Million
Q3 2020 Nov 13, 2020	BUY	$121.19 - $165.49 $399,927 - $546,117	3,300 New	3,300 $480,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.